Parnavel caps 8mg 30 pcs 1 + 1


Parnavel caps 8mg 30 pcs 1 + 1



Active substance:
Perindopril erbumine – 8.00 mg
Product form:
8 mg capsules.
At 10 or 30 tablets were placed in blisters of PVC film and aluminum foil printed patent.
30 tablets was placed in a polymeric container for medicines.
One container 1 or 3 or contour of cellular packaging together with instructions for use placed in a pile of cardboard.
Hypersensitivity to perindopril or to other components of the drug as well as other ACE inhibitors; pregnancy; breastfeeding; angioedema history (hereditary angioedema, idiopathic or due to receiving ACE inhibitors); age 18 years (effectiveness and safety have been established). The simultaneous use of aliskiren and aliskirensoderzhaschimi drugs in patients with diabetes and / yl and moderately or severely impaired renal function (glomerular filtration rate (GFR) of less than 60 ml / min / 1 73 m2 of body surface area), the simultaneous application of angiotensin receptor antagonists 11 (AR a II) in patients with diabetic nephropathy.
8 mg
– arterial hypertension;
– Chronic heart failure;
– prevention of recurrent stroke (in the complex therapy with indapamide) in patients with a history of cerebrovascular disease (stroke or transient cerebral ischemic attack);
– stable coronary heart disease (CHD): reducing the risk of cardiovascular events in patients who previously suffered a myocardial infarction and / or coronary revascularization.
pharmachologic effect
Pharmacological group:
Angiotensin converting enzyme (ACE) inhibitor
Perindopril – angiotensin converting enzyme (ACE) or kininaza II, relates to exopeptidases. Converts angiotensin I to the vasoconstrictor compound angiotensin II and destroys vasodilator bradykinin to inactive heptapeptide. Inhibition of ACE activity leads to a decrease in the concentration of angiotensin II and increasing the activity of renin in the blood plasma (suppressing negative feedback renin release) and reduced aldosterone secretion. Since ACE also destroys bradykinin, ACE inhibition leads to increased activity of circulating and tissue kallikrein-kinin system, with the system activated prostaglandins. Perindopril has therapeutic effect due to the active metabolite perindoprilat. Perindopril reduces both systolic and diastolic blood pressure (BP) in the position of “lying down” and “standing.” Perindopril decreases total peripheral vascular resistance (SVR), which leads to a reduction in blood pressure. In this case, peripheral blood flow is accelerated. However, heart rate (HR) is not increased. Renal blood flow usually increases, while the glomerular filtration rate is unchanged. The maximum antihypertensive effect is reached in 4-6 hours after a single oral administration perindopril; antihypertensive effect lasts for 24 hours. BP depression develops quickly. Stabilization of the antihypertensive effect is observed after 1 month of therapy and is maintained for a long time. Discontinuation of therapy is not accompanied by the development of the syndrome of “cancellation”. Perindopril reduces left ventricular hypertrophy. With prolonged use reduces the severity of interstitial fibrosis, normalizes isoenzyme profile myosin. Increases concentration of high density lipoprotein (HDL) in patients with hyperuricemia decreases the concentration of uric acid. Perindopril improves the elasticity of the large arteries, it eliminates the structural changes in the small arteries. Perindopril normalizes the functioning of the heart, reducing pre- and afterload. In patients with chronic heart failure (CHF) during therapy with perindopril observed:
• reducing the filling pressure in the left and right ventricles,
• reducing systemic vascular resistance,
• an increase in cardiac output and cardiac index.
Receiving the initial dose of 2 mg perindopril in patients with CHF 1-II functional class NYHA classification is not accompanied by a statistically significant reduction in blood pressure compared to placebo.
Conditions of supply of pharmacies
Dosing and Administration
Inside. It is recommended to be taken once a day, before meals, preferably in the morning, without chewing. The dose is adjusted individually for each patient depending on the severity of the disease and the individual response to treatment.
Appearance may differ from that depicted in the picture. There are contraindications. You need to read the manual or consult with a specialist

Additional information

Weight0.100 kg


There are no reviews yet.

Add your review